S. Alas

Inhibition of Constitutive STAT 3 Activity Sensitizes Resistant Non-Hodgkin ’ s Lymphoma and Multiple Myeloma to Chemotherapeutic Drug-mediated Apoptosis 1

B. Bonavida, S. Alas, 2003 .

Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.

B. Bonavida, C. Emmanouilides, S. Alas, 2000, Anticancer research.

Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.

B. Bonavida, Benjamin Bonavida, Chuen-Pei Ng, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.

B. Bonavida, C. Emmanouilides, B Bonavida, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs.

B. Bonavida, S. Alas, 2001, Cancer research.

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.

A. Demidem, B. Bonavida, N. Hanna, 1997, Cancer biotherapy & radiopharmaceuticals.

Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.

B. Bonavida, S. Alas, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.